Is Fabino Enter overvalued or undervalued?
As of September 15, 2025, Fabino Enter is considered overvalued with a PE ratio of 5.35 and a year-to-date return of -22.55%, significantly lower than its peers like Sun Pharma and Divi's Laboratories, which have much higher PE ratios.
As of 15 September 2025, the valuation grade for Fabino Enter has moved from risky to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 5.35, an EV to EBIT of 6.75, and a ROE of 3.03%. In comparison to its peers, Fabino Enter's PE ratio is significantly lower than that of Sun Pharma Industries, which stands at 33.52, and Divi's Laboratories at 69.55, both categorized as expensive or very expensive. Additionally, while Fabino Enter's PEG ratio is 0.00, indicating no growth expectations, its peers like Cipla and Dr. Reddy's Labs show more favorable valuations at 1.09 and 9.47 respectively. The company's stock has underperformed relative to the Sensex, with a year-to-date return of -22.55% compared to the Sensex's 4.67%, reinforcing the view that Fabino Enter is overvalued.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
